RADEK SKODA to Young Adult
This is a "connection" page, showing publications RADEK SKODA has written about Young Adult.
Connection Strength
0.198
-
Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms. Blood. 2014 Apr 03; 123(14):2220-8.
Score: 0.041
-
Evidence for a founder effect of the MPL-S505N mutation in eight Italian pedigrees with hereditary thrombocythemia. Haematologica. 2009 Oct; 94(10):1368-74.
Score: 0.030
-
The allele burden of JAK2 mutations remains stable over several years in patients with myeloproliferative disorders. Haematologica. 2008 Dec; 93(12):1890-3.
Score: 0.028
-
Identification of Hepatic-like EPO as a Cause of Polycythemia. N Engl J Med. 2025 May 01; 392(17):1684-1697.
Score: 0.022
-
Impact of treatment for adolescent and young adults with essential thrombocythemia and polycythemia vera. Leukemia. 2025 May; 39(5):1135-1145.
Score: 0.022
-
Real-world study of children and young adults with myeloproliferative neoplasms: identifying risks and unmet needs. Blood Adv. 2022 09 13; 6(17):5171-5183.
Score: 0.019
-
Clonal hematopoiesis in donors and long-term survivors of related allogeneic hematopoietic stem cell transplantation. Blood. 2020 04 30; 135(18):1548-1559.
Score: 0.016
-
Dkk3 levels in patients with myeloproliferative neoplasms. Thromb Res. 2014 Feb; 133(2):218-21.
Score: 0.010
-
Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations. Blood. 2011 Mar 10; 117(10):2813-6.
Score: 0.008